Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of “Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned a consensus rating of “Buy” from the eleven analysts that are covering the company, Marketbeat reports. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $58.20.

Several research analysts recently weighed in on MIRM shares. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $47.02 on Tuesday. The firm has a fifty day moving average of $47.95 and a two-hundred day moving average of $43.75. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.28 and a beta of 1.04. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron bought 1,335 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was bought at an average cost of $45.57 per share, for a total transaction of $60,835.95. Following the purchase, the director now owns 163,643 shares of the company’s stock, valued at $7,457,211.51. The trade was a 0.82 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jolanda Howe sold 750 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the sale, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. This trade represents a 20.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 133,679 shares of company stock worth $6,007,081 in the last ninety days. Insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp lifted its stake in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after buying an additional 297,511 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Mirum Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after acquiring an additional 17,149 shares during the period. Geode Capital Management LLC lifted its position in Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after acquiring an additional 29,017 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after acquiring an additional 29,545 shares during the period. Finally, AlphaQuest LLC grew its position in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.